Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, Australia.
Acta Diabetol. 2024 Feb;61(2):181-188. doi: 10.1007/s00592-023-02193-x. Epub 2023 Oct 9.
This study aims to describe the prevalence of monogenic diabetes in an Australian referral cohort, in relation to Exeter maturity-onset diabetes of the young (MODY) probability calculator (EMPC) scores and next-generation sequencing with updated testing where relevant.
State-wide 5-year retrospective cohort study of individuals referred for monogenic diabetes genetic testing.
After excluding individuals who had cascade testing for a familial variant (21) or declined research involvement (1), the final cohort comprised 40 probands. Incorporating updated testing, the final genetic result was positive (likely pathogenic/pathogenic variant) in 11/40 (27.5%), uncertain (variant of uncertain significance) in 8/40 (20%) and negative in 21/40 (52.5%) participants. Causative variants were found in GCK, HNF1A, MT-TL1 and HNF4A. Variants of uncertain significance included a novel multi-exonic GCK duplication. Amongst participants with EMPC scores ≥ 25%, a causative variant was identified in 37%. Cascade testing was positive in 9/10 tested relatives with diabetes and 0/6 tested relatives with no history of diabetes.
Contemporary genetic testing produces a high yield of positive results in individuals with clinically suspected monogenic diabetes and their relatives with diabetes, highlighting the value of genetic testing for this condition. An EMPC score cutoff of ≥ 25% correctly yielded a positive predictive value of ≥ 25% in this multiethnic demographic. This is the first Australian study to describe EMPC scores in the Australian clinic setting, albeit a biased referral cohort. Larger studies may help characterise EMPC performance between ethnic subsets, noting differences in the expected probability of monogenic diabetes relative to type 2 diabetes.
本研究旨在描述澳大利亚转诊队列中单基因糖尿病的流行情况,以及与 Exeter 成熟型青年糖尿病(MODY)可能性计算器(EMPC)评分和相关的下一代测序的关系。
对接受单基因糖尿病遗传检测的个体进行了为期 5 年的全州回顾性队列研究。
排除了有家族变异进行级联检测的个体(21 例)或拒绝参与研究的个体(1 例)后,最终队列由 40 名先证者组成。纳入更新的检测后,最终的遗传结果为阳性(可能致病性/致病性变异)11/40(27.5%),不确定(意义不明的变异)8/40(20%),阴性 21/40(52.5%)。致病变异位于 GCK、HNF1A、MT-TL1 和 HNF4A。不确定意义的变异包括一种新的多外显子 GCK 重复。在 EMPC 评分≥25%的参与者中,有 37%发现了致病变异。在 10 名有糖尿病的亲属中进行级联检测,阳性 9 例,在 6 名无糖尿病史的亲属中检测为阴性。
当代基因检测在临床疑似单基因糖尿病患者及其有糖尿病的亲属中产生了较高的阳性结果,突出了基因检测在这种情况下的价值。EMPC 评分≥25%的截断值在这种多民族人群中正确地产生了≥25%的阳性预测值。这是澳大利亚第一份描述澳大利亚临床环境中 EMPC 评分的研究,尽管这是一个有偏差的转诊队列。更大的研究可能有助于描述不同种族亚组之间 EMPC 的性能,注意单基因糖尿病与 2 型糖尿病的预期概率差异。